mr

Moderna

MRNA
NASDAQ
$169.04

Moderna a-t-elle un rempart concurrentiel (moat) solide ?

Moderna shows limited evidence of a durable competitive moat. Margins and returns on capital are below levels that would indicate meaningful competitive advantages. The business may struggle to maintain its current profitability as competitive dynamics evolve.